FASENRA

NDC 0310-1730 · AstraZeneca Pharmaceuticals LP

Generic nameBenralizumab

Dosage formINJECTION, SOLUTION

RouteSUBCUTANEOUS

Active ingredient(s)BENRALIZUMAB

Strength30 mg/mL

Pharmacologic classInterleukin 5 Receptor alpha-directed Antibody Interactions [MoA], Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]

Marketing categoryBLA

Packages

0310-1730-30 — 1 SYRINGE, GLASS in 1 CARTON (0310-1730-30) / 1 mL in 1 SYRINGE, GLASS

0310-1730-85 — 1 SYRINGE, GLASS in 1 CARTON (0310-1730-85) / 1 mL in 1 SYRINGE, GLASS

Billed under HCPCS

J0517 — Injection, benralizumab, 1 mg Medicare Part B payment limit (ASP + 6%): $165.08

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

0310-1745 — Benralizumab, 0310-1830 — Benralizumab

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q4 (October 2026 release). All data sources · How to read the labels

Current data releases:ICD-10-CM FY2027 · ICD-10-PCS FY2027 · HCPCS October 2026 · MS-DRG v44 · Medicare Code Editor v44.0 · NCCI PTP Q4 2026 · MUE Q4 2026 · NCD code lists 2026-01 · LCD export September 28, 2026 · All releases and sources